Please assess the completion status of the following clinical trial:

Trial Title: Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Assessed between 20 and 24 months of pregnancy~* Pregnancy known before 24 weeks of gestation~* Documented HIV-1 infection without indication for ARV therapy~* CD4 count above or equal to 350 per mm3~* VL under 30 000 copies per ml~* Naïve for PI (except treatment during previous pregnancy)~* Informed consent signed~Exclusion Criteria:~* HIV2 infection or HIV1 group O infection~* Any pathology related to pregnancy~* Contra-indication to study drugs~* Unstable hypertension or diabetes~* Known risk of premature delivery~* In case of previous treatment with a protease inhibitor : presence of resistance mutations on the HIV-1 protease gene by genotyping analysis (1 mutation among V32I et I47A, I50V V82A/F/S/T, I84V, L90 M or more than 3 mutations among L10 F/I/R/V, K20/M/R, L24I, L33F, M46I/L, F53L, I54M/L/T/V, L63P, A71L/V/T,)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Kaletra (lopinavir/ritonavir)
- 2 (Type: ACTIVE_COMPARATOR): Kaletra (lopinavir/ritonavir) + Combivir (zidovudine/lamivudine)

Based on this trial design, predict the completion outcome and termination type (if applicable).